Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

  • Tenmile and Novo Holdings are core investors
  • Cristina LarkinBruce Montgomery, and Michael Lamprecht to join the Board of Directors
  • Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms

SAN FRANCISCOJan. 5, 2024 – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced the appointment of Cristina LarkinBruce Montgomery, MD, and Michael Lamprecht, PhD, to its board of directors in conjunction with closing its Series B funding round from core investors Tenmile and Novo Holdings. Ryan Cirz, PhD, Chief Executive Officer and director, highlighted these developments as important milestones in the growth of the Company that will enable its mission of creating life-changing antibiotics through scientific innovation and strategic leadership.

Read more…